Cemiplimab (REGN2810)
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for Cemiplimab (REGN2810), covering 2024-10-09 to 2026-02-23. Get the full timeline:
Most recent: Clinical Trial Update: Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) [Phase 3]